Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial

Catheterization and Cardiovascular Interventions

Volumn 70, Issue 1, 2007, Pages 44-51

  Dery, Jean Pierre ^a   Campbell, Mark E ^b   Mathias, Jasmine ^c   Pieper, Karen S ^c   Harrington, Robert A ^c   Madan, Mina ^d   Gibson, C Michael ^e   Tolleson, Thaddeus R ^f   O'Shea, J Conor ^g   Tcheng, James E ^c,h  

^a LAVAL UNIVERSITY   (Canada)

^b USAF Medical Center Keesler   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^f Mother Frances Hospital   (United States)

^g BON SECOURS HOSPITAL   (Ireland)

^h DUKE UNIVERSITY   (United States)

Author keywords

Antiplatelet therapy; Glycoprotein IIb IIIa inhibitor; Percutaneous coronary intervention; Stent

Indexed keywords

CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; INTEGRIN; PLACEBO; THIENO[2,3 B]PYRIDINE DERIVATIVE; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DEATH; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG USE; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA;

EID: 34447115693     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21059     Document Type: Article

References (21)

1. Barnathan ES, Schwartz JS, Taylor L, et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987;76:125-134.
2. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089.
3. Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998;98:2126-2132.
4. Rupprecht HJ, Darius H, Borkowski U, et al. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation 1998;97:1046-1052.
5. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-1671.
6. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
7. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
8. The EPISTENT Investigators. Randomised placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein- IIb/IIIa blockade. Lancet 1998;352:87-92.
9. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. Lancet 2000;356:2037-2044.
10. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet 1997;349:1429-1435.
11. Steinhubl S, Ellis S, Wolski K, Lincoff A, Topol E, for theEPISTENT Investigators. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events. Data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation 2001;103:1403-1409.
12. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE Study. Lancet 2001;358:527-533.
13. Assali AR, Salloum J, Sdringola S, et al. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). Am J Cardiol 2001;88:884-886.
14. Steinhubl SR, Berger PB, Mann JT III, Fry ETA, DeLago A, Wilmer C, Topol EJ, for theClopidogrel for the Reduction of Events During Observation (CREDO) Investigators. JAMA 2002;288:2411-2420.
15. Nikhil JY, Radhakrishnan S, Paradiso-Hardy FL, Cohen EA. Clopidogrel in interventional cardiology: Questions answered and questions remaining. Can J Cardiol 2002;7:739-748.
16. Chan AW, Moliterno DJ, Berger PB, et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: Results from the Do Tirofiban and ReoPro Give Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol 2003;42:1188-1195.
17. Tcheng JE, Campbell ME. Platelet inhibition strategies in percutaneous coronary intervention: Competition or coopetition? J Am Coll Cardiol 2003;42:1196-1198.
18. O'Shea JC, Madan M, Cantor WJ, et al. Design and methodology of the ESPRIT trial: Evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention. Am Heart J 2000;140:834-839.
19. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural MI in patients undergoing coronary intervention: Results from the ARMYDA-2 (Antiplatelet Therapy for Reduction of MYocardial Damage during Angioplasty) Study. Circulation 2005;111:2099-2106.
20. Kastrati A, Mehilli J, Schuhlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Bollwein H, Volmer C, Gawaz M, Berger PB, Schomig A;Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment (ISAR-REACT) Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004;350:232-238.
21. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) Study. Circulation 2005;111:1153-1159.